In our results, ASO treatment led to a reduction in TDP‐43 pathology, which was accompanied by improved behavioural outcomes in VCP A232E mice, highlighting the therapeutic potential of reducing TDP‐43 dysregulation in multisystem proteinopathy. The gene discussed is VCP; the disease is proteostasis deficiencies.